InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Genomic & Epigenomic Profiling Market Size, Share & Trends Analysis Report, By Type (Genomic Profiling and Epigenomic Profiling), By Application (Clinical Diagnostics, Agriculture & Animal Research, and Drug Discovery & Development), By Technology (NGS, PCR-based, and Microarray), By End-use (Hospitals, Pharmaceuticals, and Research Institutes),-Market Outlook And Industry Analysis 2034″
Genomic & Epigenomic Profiling Market Size is valued at US$ 5.5 Bn in 2024 and is predicted to reach US$ 23.2 Bn by the year 2034 at an 15.8% CAGR during the forecast period for 2025-2034.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3271
Genomic and epigenomic profiling are cutting-edge scientific techniques for analyzing the genetic and regulatory environments of an organism’s cells. Genomic profiling searches for single-nucleotide variants, insertions/deletions, copy-number changes, and structural rearrangements using methods like whole-genome or targeted sequencing and genotyping arrays. But without altering the underlying nucleotide sequence, epigenomic profiling examines chemical and structural markers that regulate how the genome is used.
The primary factors propelling the market’s expansion include rising rates of cancer and rare disorders, advancements in genomic and epigenomic profiling technologies, and a growing emphasis on individualized healthcare solutions worldwide. Additionally, during the projection period, the growth of the genomic and epigenomic profiling market will be accelerated by pharmaceutical and biotech companies investing more in the development of precision medications.
List of Prominent Players in the Genomic & Epigenomic Profiling Market:
- Illumina
- Thermo Fisher Scientific
- Agilent Technologies
- Bio-Rad Laboratories
- Roche
- Qiagen
- PerkinElmer
- Pacific Biosciences
- BGI Genomics
- New England Biolabs
- Merck KGaA
- Diagenode
- Promega Corporation
- 10x Genomics
- Oxford Nanopore Technologies
- QIAGEN
- Zymo Research
- Fulgent Genetics
- GENEWIZ
- Eurofins Scientific
- Invitae
- Myriad Genetics
- Adaptive Biotechnologies
- Guardant Health
- Invivoscribe
- Others
Read Overview Report– https://www.insightaceanalytic.com/report/genomic-and-epigenomic-profiling-market/3271
Market Dynamics:
Drivers-
The genomic and epigenomic profiling market is expanding due to advancements in high-throughput sequencing technologies that reduce costs and improve accessibility. Additionally, the demand for molecular diagnostics and personalized medicine is being driven by the increasing prevalence of complex diseases, including cancer, neurological disorders, and autoimmune conditions, which is propelling market expansion.
The genomic and epigenomic profiling market is expanding rapidly as pharmaceutical and biotech companies invest in the development of targeted treatments. Furthermore, greater clinical trial incorporation of genetic profiling, increased government financing, and expanded research activities are significant drivers of the expansion of the genomic and epigenomic profiling market.
Challenges:
One of the biggest challenges to the market’s growth is managing huge, complex genomic and epigenomic data, which requires advanced computing capabilities and bioinformatic expertise. The requirement to standardize laboratory standards and analytical methods across multiple platforms complicates data reliability. This is expected to limit growth in the genomic and epigenomic profiling market. Additionally, maintaining data privacy and complying with evolving regulations such as GDPR influences market participants. Scientists are still struggling to translate their understanding of epigenomics into practical therapeutic outcomes. Furthermore, regulatory ambiguity about novel assays hinders prompt approvals and reimbursement.
Regional Trends:
The global genomic and epigenomic profiling market was dominated by the North American region in 2024 due to various factors. North America is known for its sophisticated healthcare system and significant R&D expenditures. Widespread access to state-of-the-art technologies and the adoption of novel medical procedures, such as genomic and epigenomic profiling, are made possible by the region’s strong healthcare system. Additionally, the need for precision medicine has been fueled by the increased incidence of chronic illnesses like cancer, heart disease, and neurological conditions in North America. By offering individualized insights into each patient’s genetic composition and directing tailored medicines and treatment approaches, genomic and epigenomic profiling is essential to precision medicine.
Over the forecast period, the Asia Pacific region is poised to become the fastest-growing market for comprehensive genomic and epigenomic profiling, driven by expanding healthcare spending, growing precision medicine awareness, and favorable government regulations. The region is poised to be a major growth market for the global genomic and epigenomic profiling market, driven by significant investments from nations such as China, Japan, South Korea, and India in genomic research, infrastructure development, and capacity building. Furthermore, the Asia Pacific genomic and epigenomic profiling market is anticipated to expand and innovate further as population-scale genetic screening programs grow and cutting-edge diagnostic technologies become more accessible.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customization/3271
Recent Developments:
- November 2024: The Phase I clinical trials for MyCHELANGELTM, an epigenomic controller that targets uncommon disorders, were successfully completed, according to Omega Therapeutics, indicating advancements in therapeutic epigenetic modulation.
Segmentation of Genomic & Epigenomic Profiling Market-
Genomic & Epigenomic Profiling Market- By Type
- Genomic Profiling
- Epigenomic Profiling
Genomic & Epigenomic Profiling Market- By Application
- Clinical Diagnostics
- Agriculture & Animal Research
- Drug Discovery & Development
Genomic & Epigenomic Profiling Market- By Technology
Genomic & Epigenomic Profiling Market- By End-use
- Hospitals
- Pharmaceuticals
- Research Institutes
Genomic & Epigenomic Profiling Market- By Region
North America-
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
